Incyte Enters A Data-Rich Year On Path To Portfolio Diversification

Myelofibrosis, Dermatology, Oncology Readouts Ahead

 
• By Mandy Jackson

Incyte’s Jakafi-dominated portfolio gained Opzelura as a second source of significant revenue in 2021. While further diversification has been limited, new and existing R&D assets may deliver upside in 2024.

Science Research as a Concept for Presentation
Incyte anticipates many trial readouts and other R&D milestones in 2024 • Source: Shutterstock

More from Anticancer

More from Therapy Areas